Physician profile
John Fx Horan
NPI 1679567531
$8,786.72
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,162 · 2020: $1,053 · 2021: $3,198 · 2022: $1,264 · 2023: $91.79 · 2024: $18.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,218.44 | 2019-2022 | |
| Abbvie INC. | $1,133.77 | 2019-2024 | |
| Pfizer INC. | $861.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $764.64 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $453.72 | 2019-2022 | |
| Lilly USA, LLC | $347.26 | 2019-2022 | |
| Novo Nordisk INC | $235.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $233.82 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $213.78 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $198.07 | 2019-2022 | |
| Amarin Pharma, INC. | $194.95 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $178.01 | 2019-2022 | |
| Antares Pharma, INC. | $169.51 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.93 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Horan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.